Sunesis Pharmaceuticals (NASDAQ: SNSS) and Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitabiliy.

Profitability

This table compares Sunesis Pharmaceuticals and Biohaven Pharmaceutical Holding Co’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sunesis Pharmaceuticals -1,472.94% N/A -109.38%
Biohaven Pharmaceutical Holding Co N/A N/A -172.50%

Analyst Ratings

This is a summary of recent ratings and target prices for Sunesis Pharmaceuticals and Biohaven Pharmaceutical Holding Co, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sunesis Pharmaceuticals 0 2 1 0 2.33
Biohaven Pharmaceutical Holding Co 0 0 5 0 3.00

Sunesis Pharmaceuticals presently has a consensus price target of $3.00, indicating a potential upside of 15.83%. Biohaven Pharmaceutical Holding Co has a consensus price target of $31.75, indicating a potential upside of 28.39%. Given Biohaven Pharmaceutical Holding Co’s stronger consensus rating and higher probable upside, analysts clearly believe Biohaven Pharmaceutical Holding Co is more favorable than Sunesis Pharmaceuticals.

Valuation & Earnings

This table compares Sunesis Pharmaceuticals and Biohaven Pharmaceutical Holding Co’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Sunesis Pharmaceuticals $2.57 million 21.63 -$36.02 million ($2.25) -1.15
Biohaven Pharmaceutical Holding Co N/A N/A -$72.14 million N/A N/A

Sunesis Pharmaceuticals has higher revenue and earnings than Biohaven Pharmaceutical Holding Co.

Institutional & Insider Ownership

55.2% of Sunesis Pharmaceuticals shares are owned by institutional investors. 10.2% of Sunesis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Sunesis Pharmaceuticals beats Biohaven Pharmaceutical Holding Co on 5 of the 9 factors compared between the two stocks.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.